Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
The leap from academia to industry

The earlier in development, the greater the risk. It’s an unspoken law in biotech that makes valorizing promising academic projects difficult to f…


CD3 as co-creator of drugs with academia and pharma

The Center for Drug Design and Discovery (CD3), based in Leuven, bridges the gap between innovative biomedical research emerging from academic ins…


Reversed Brexit: £250 million for Bart De Strooper's dementia research

The UK has pledged a budget of £250 million to the creation of the UK Dementia Research Institute (DRI). The institute hopes to assemble top-notch…

POPULAR TAGS

Take your own venture and make it a business case

Written by GK on in the category quick facts with the tags , , .


The Executive Master of Business Innovation & Entrepreneurship in Life Sciences & Health (MBI Life Sciences and Health) is a unique ‘hands-on’ MBA program to accelerate life sciences ventures or businesses. The course addresses start-up/growth companies in life sciences, keen to boost their entrepreneurial business. The participants will work on their own venture as the business cases and not generic examples used in regular business schools. Moreover, the course is adapted to the specific needs of the life sciences and healthcare industry unlike any other MBA program. The team of coaches experienced in life sciences will help the new company owners to bring their business to the next level.

MBI Life Sciences & Health will start at the beginning of the next academic year in Flanders offering a world-class educational program thanks to the contribution of VIB, FlandersBio and Vlerick Business School. The courses will take place both in Belgium (50%) and the Netherlands (50%) in collaboration with UMC Utrecht, Utrecht University, Maastricht UMC, Radboud UMC, MIRA and Health Valley. The candidates are currently being preselected.

Read more about: , , .

RELATED ARTICLES
The leap from academia to industry

The earlier in development, the greater the risk. It’s an unspoken law in biotech that makes valorizing promising academic projects difficult to f…


CD3 as co-creator of drugs with academia and pharma

The Center for Drug Design and Discovery (CD3), based in Leuven, bridges the gap between innovative biomedical research emerging from academic ins…


Reversed Brexit: £250 million for Bart De Strooper's dementia research

The UK has pledged a budget of £250 million to the creation of the UK Dementia Research Institute (DRI). The institute hopes to assemble top-notch…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

KU Leuven V-Bio Ventures Itera Life Science UGent GSK Flanders.bio Janssen Biowin Turnstone XpandInnovation

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.